Governments Need Better Guidance to Maximise Value for Money: The Case of Australia’s Pharmaceutical Benefits Advisory Committee
Crossref DOI link: https://doi.org/10.1007/s40258-015-0220-3
Published Online: 2016-01-27
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Carter, Drew
Vogan, Arlene
Haji Ali Afzali, Hossein
Funding for this research was provided by:
National Health and Medical Research Council (AU) (565501, 565501)
Text and Data Mining valid from 2016-01-27